Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in
Pre-market
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverFMS
HealthcareNYQUSD

Fresenius Medical Care AG

$0012345678900123456789.0012345678900123456789-0.5%
52w low $20.02$27.64 52w high
Market data · updated 7h ago
Market data
Market cap
$13.26B
52w range
$20.02 - $27.64
Beta
0.82
Sector
Healthcare
Data quality
100/100
Valuation
P/E ratio
12.9x
fair value estimate
$27.99
Margin of safety
+25.7%
Forward P/E
6.8x
PEG ratio
0.85
Dividend yield
3.62%
Quality & efficiency
Moat score
33/100
Return on equity
7.9%
Profit margin
4.9%
Debt / equity
0.78
Growth & analysts
Revenue growth
-5.5%
Analyst target
$25.66
Target upside
+15.3%
Analysts
7
Run the 10-point checklist before you buy How these numbers are made

About Fresenius Medical Care AG

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Valuation

ValueGrowthProfitHealthIncome52QUALITY
Overall Rating
57
Good quality
Good quality

Derived from filed metrics · High confidence (100% of the inputs available)

Moat Score33
Fair value estimate
$27.99+25.7% upside

Moat, fair value and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$13.26B
P/E Ratio
12.9
Dividend Yield
3.62%
Revenue Growth
-5.5%
Profit Margin
4.9%
ROE
7.9%
Debt / Equity
0.78
Beta
0.82
ValueDividend Aristocrats

Statistics

Similar Stocks · Healthcare

Latest News · FMS